Study Findings from Baltimore Advance Knowledge in Drugs and Therapies (Preclinical Evaluation of a New Series of Albumin-Binding <superscript>177</superscript>Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics).
In: Clinical Trials Week, 2023-09-11, S. 2069-2069
serialPeriodical
Zugriff:
According to the news editors, the research concluded: "Conclusions: SP 177 sp Lu-Alb-L4 and SP 177 sp Lu-Alb-L6 showed high tumor uptake in PSMA+ tumors and tumor-to-blood ratios. The area under the curve (AUC [ [0-192h] ]) of the PSMA+ PC3 PIP tumor uptake of SP 177 sp Lu-Alb-L4 and SP 177 sp Lu-Alb-L5 were >4-fold higher than SP 177 sp Lu-Alb-L2, SP 177 sp Lu-Alb-L3, and SP 177 sp Lu-Alb-L6, respectively. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Study Findings from Baltimore Advance Knowledge in Drugs and Therapies (Preclinical Evaluation of a New Series of Albumin-Binding <superscript>177</superscript>Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics).
|
---|---|
Zeitschrift: | Clinical Trials Week, 2023-09-11, S. 2069-2069 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|